Physician

Jay Christopher Andersen, M.D.

According to 2025 Medicare claims, Jay Andersen, M.D. (NPI: 1922001023) practices hematology/oncology in the Portland-Vancouver-Hillsboro, OR-WA market, with the plurality of this provider's patient population coming from Washington, OR. This provider's primary affiliated billing organization is NORTHWEST CANCER SPECIALISTS PC (NPI: 1407828114; TIN: 931280206) and primary practice location at 97223-8514. Andersen is affiliated with the PSW ACO (ACO ID: A5323), participating under the MSSP model.

Andersen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 411 traditional Medicare patients, billed 102,012 HCPCS/CPT codes, and received $1,477,628 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,254 prescription claims across 267 beneficiaries totaling $2,637,559 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 32 claims. Open Payments data shows 231 records totaling $617,351. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $257,284 to $1,477,628. Similarly, Part D prescription costs have moved sharply higher in recent years, from $861,122 to $2,637,559. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	223	23,879	$257,284
2016	228	19,544	$391,124
2017	215	26,050	$414,591
2018	233	20,413	$414,731
2019	379	57,076	$827,888
2020	366	77,865	$894,744
2021	405	86,571	$1,150,137
2022	419	87,775	$1,223,727
2023	402	78,237	$1,122,637
2024	411	102,012	$1,477,628

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	193	1,343	$861,122
2016	203	1,459	$1,365,113
2017	211	1,209	$1,736,133
2018	198	1,125	$1,523,358
2019	232	1,196	$2,343,860
2020	222	1,256	$2,438,074
2021	257	1,308	$3,309,063
2022	280	1,420	$3,587,812
2023	281	1,344	$3,545,057
2024	267	1,254	$2,637,559

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	37	$6,185
2019	N/R	N/R	N/R
2020	N/R	14	$2,596
2021	N/R	90	$6,846
2022	N/R	N/R	N/R
2023	N/R	32	$2,942
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	99	227	$109
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	118	164	$92
80053	Blood test, comprehensive group of blood chemicals	126	410	$10
36415	Insertion of needle into vein for collection of blood sample	126	323	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	128	462	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	28	784	$434,279
Verzenio	Abemaciclib	25	700	$367,298
Lenvima	Lenvatinib Mesylate	11	330	$268,654
Afinitor	Everolimus	12	336	$230,183
Kisqali	Ribociclib Succinate	14	392	$214,497

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$533	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	225	$616,818	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jay Christopher Andersen, M.D.?

Tedicare shows public-source Medicare data for Jay Christopher Andersen, M.D. (NPI 1922001023), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jay Christopher Andersen, M.D. have ACO affiliation data?

Jay Christopher Andersen, M.D. is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323).

What billing organization is linked to Jay Christopher Andersen, M.D.?

Jay Christopher Andersen, M.D. is linked to NORTHWEST CANCER SPECIALISTS PC (billing NPI 1407828114) in the available physician profile data.

Does Jay Christopher Andersen, M.D. have Open Payments data?

Jay Christopher Andersen, M.D. has 231 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.